{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:19:29Z","timestamp":1779333569930,"version":"3.51.4"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T00:00:00Z","timestamp":1695081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-026401, INV-039901"],"award-info":[{"award-number":["INV-026401, INV-039901"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Aerogen Pharma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Respiratory distress syndrome in preterm infants is an important cause of morbidity and mortality. Less invasive methods of surfactant administration, along with the use of continuous positive airway pressure (CPAP), have improved outcomes of preterm infants. Aerosolized surfactant can be given without the need for airway instrumentation and may be employed in areas where these skills are scarce. Recent trials from high-resourced countries utilising aerosolized surfactant have had a low quality of evidence and varying outcomes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and analysis<\/jats:title>\n                <jats:p>The Neo-INSPIRe trial is an unblinded, multicentre, randomised trial of a novel aerosolized surfactant drug\/device combination. Inclusion criteria include preterm infants of 27\u201334<jats:sup>+6<\/jats:sup>\u00a0weeks\u2019 gestational age who weigh 900-1999g and who require CPAP with a fraction of inspired oxygen (FiO<jats:sub>2<\/jats:sub>) of 0.25\u20130.35 in the first 2\u201324\u00a0h of age. Infants are randomised 1:1 to control (CPAP alone) or intervention (CPAP with aerosolized surfactant). The primary outcome is the need for intratracheal bolus surfactant instillation within 72\u2005h of age. Secondary outcomes include the incidence of reaching failure criteria (persistent FiO2 of\u2009&gt;\u20090.40, severe apnoea or severe work of breathing), the need for and duration of ventilation and respiratory support, bronchopulmonary dysplasia and selected co-morbidities of prematurity. Assuming a 40% relative risk reduction to reduce the proportion of infants requiring intratracheal bolus surfactant from 45 to 27%, the study will aim to enrol 232 infants for the study to have a power of 80% to detect a significant difference with a type 1 error of 0.05.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Ethics and dissemination<\/jats:title>\n                <jats:p>Ethical approval has been granted by the relevant human research ethics committees at University of Cape Town (HREC 681\/2022), University of the Witwatersrand HREC (221112) and Stellenbosch University (M23\/02\/004).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>PACTR202307490670785<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12887-023-04296-4","type":"journal-article","created":{"date-parts":[[2023,9,19]],"date-time":"2023-09-19T11:02:06Z","timestamp":1695121326000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A multicentre neonatal interventional randomised controlled trial of nebulized surfactant for preterm infants with respiratory distress: Neo-INSPIRe trial protocol"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8227-0247","authenticated-orcid":false,"given":"Ilse","family":"Lategan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1181-0941","authenticated-orcid":false,"given":"David","family":"Durand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-9341","authenticated-orcid":false,"given":"Michael","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8884-2517","authenticated-orcid":false,"given":"Firdose","family":"Nakwa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9245-3282","authenticated-orcid":false,"given":"Lizelle","family":"Van Wyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-8485","authenticated-orcid":false,"given":"Sithembiso","family":"Velaphi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7795-4900","authenticated-orcid":false,"given":"Alan","family":"Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1426-1207","authenticated-orcid":false,"given":"Gugu","family":"Kali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0288-3014","authenticated-orcid":false,"given":"Roger","family":"Soll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1215-1124","authenticated-orcid":false,"given":"Danielle","family":"Ehret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9046-759X","authenticated-orcid":false,"given":"Heather","family":"Zar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-9996","authenticated-orcid":false,"given":"Lloyd","family":"Tooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,9,19]]},"reference":[{"key":"4296_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1651-2227.2011.02543.x","volume":"101","author":"K Bohlin","year":"2012","unstructured":"Bohlin K. RDS\u2013CPAP or surfactant or both. Acta Paediatr. 2012;101:24\u20138.","journal-title":"Acta Paediatr"},{"issue":"4","key":"4296_CR2","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1159\/000499361","volume":"115","author":"DG Sweet","year":"2019","unstructured":"Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, et al. European consensus guidelines on the management of respiratory distress syndrome\u20132019 update. Neonatology. 2019;115(4):432\u201350.","journal-title":"Neonatology"},{"issue":"1","key":"4296_CR3","doi-asserted-by":"publisher","first-page":"e20180902","DOI":"10.1542\/peds.2018-0902","volume":"143","author":"EE Foglia","year":"2019","unstructured":"Foglia EE, Ades A, Sawyer T, Glass KM, Singh N, Jung P, et al. Neonatal intubation practice and outcomes: an international registry study. Pediatrics. 2019;143(1):e20180902.","journal-title":"Pediatrics"},{"issue":"1","key":"4296_CR4","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.bja.2020.04.051","volume":"125","author":"L Armstrong","year":"2020","unstructured":"Armstrong L, Harding F, Critchley J, McNarry AF, Myatra SN, Cooper R, et al. An international survey of airway management education in 61 countries. Br J Anaesth. 2020;125(1):e54\u201360.","journal-title":"Br J Anaesth"},{"key":"4296_CR5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.jpeds.2022.02.054","volume":"246","author":"C Dani","year":"2022","unstructured":"Dani C, Talosi G, Piccinno A, Ginocchio VM, Balla G, Lavizzari A, et al. A randomized, controlled trial to investigate the efficacy of nebulized poractant alfa in premature babies with respiratory distress syndrome. J Pediatr. 2022;246:40-47.e5.","journal-title":"J Pediatr"},{"issue":"1","key":"4296_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1136\/archdischild-2021-321645","volume":"107","author":"L Jardine","year":"2022","unstructured":"Jardine L, Lui K, Liley HG, Schindler T, Fink J, Asselin J, et al. Trial of aerosolised surfactant for preterm infants with respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 2022;107(1):51\u20135.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"4296_CR7","doi-asserted-by":"publisher","first-page":"e20193967","DOI":"10.1542\/peds.2019-3967","volume":"146","author":"JJ Cummings","year":"2020","unstructured":"Cummings JJ, Gerday E, Minton S, Katheria A, Albert G, Flores-Torres J, et al. Aerosolized calfactant for newborns with respiratory distress: a randomized trial. Pediatrics. 2020;146(5):e20193967.","journal-title":"Pediatrics"},{"issue":"5","key":"4296_CR8","doi-asserted-by":"publisher","first-page":"e2020021576","DOI":"10.1542\/peds.2020-021576","volume":"146","author":"K Glaser","year":"2020","unstructured":"Glaser K, Wright CJ. Aerosolized calfactant in infants with RDS: surfactant replacement 2.0? Pediatrics. 2020;146(5):e2020021576.","journal-title":"Pediatrics"},{"issue":"3","key":"4296_CR9","doi-asserted-by":"publisher","first-page":"F313","DOI":"10.1136\/archdischild-2018-315051","volume":"104","author":"S Minocchieri","year":"2019","unstructured":"Minocchieri S, Berry CA, Pillow JJ. Nebulised surfactant to reduce severity of respiratory distress: a blinded, parallel, randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2019;104(3):F313\u20139.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"5","key":"4296_CR10","doi-asserted-by":"publisher","first-page":"e2021052504","DOI":"10.1542\/peds.2021-052504","volume":"148","author":"VD Gaertner","year":"2021","unstructured":"Gaertner VD, Thomann J, Bassler D, R\u00fcegger CM. Surfactant nebulization to prevent intubation in preterm infants: a systematic review and meta-analysis. Pediatrics. 2021;148(5):e2021052504.","journal-title":"Pediatrics"},{"issue":"2","key":"4296_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/apa.16050","volume":"111","author":"L Tooke","year":"2022","unstructured":"Tooke L, Ehret DE, Okolo A, Dlamini-Nqeketo S, Joolay Y, Minto\u2019o S, et al. Limited resources restrict the provision of adequate neonatal respiratory care in the countries of Africa. Acta Paediatr. 2022;111(2):275\u201383.","journal-title":"Acta Paediatr"},{"issue":"4","key":"4296_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1159\/000337354","volume":"101","author":"JJ Pillow","year":"2012","unstructured":"Pillow JJ, Minocchieri S. Innovation in surfactant therapy II: surfactant administration by aerosolization. Neonatology. 2012;101(4):337\u201344.","journal-title":"Neonatology"},{"issue":"3","key":"4296_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","volume":"158","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, G\u00f8tzsche PC, Krle\u017ea-Jeri\u0107 K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200\u20137.","journal-title":"Ann Intern Med"},{"key":"4296_CR14","doi-asserted-by":"publisher","first-page":"817817","DOI":"10.3389\/fgwh.2022.817817","volume":"3","author":"I Lategan","year":"2022","unstructured":"Lategan I, Price C, Rhoda NR, Zar HJ, Tooke L. Respiratory interventions for preterm infants in LMICs: a prospective study from Cape Town, South Africa. Front Glob Women\u2019s Health. 2022;3:817817.","journal-title":"Front Glob Women\u2019s Health"},{"key":"4296_CR15","unstructured":"WHO. Target product profile for aerosolized surfactant therapy in neonates with respiratory distress syndrome in low- and middle-income countries. https:\/\/www.who.int\/publications\/i\/item\/9789240067851. Accessed 15 June 2023."}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12887-023-04296-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-023-04296-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T13:25:43Z","timestamp":1700573143000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-023-04296-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,19]]},"references-count":15,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4296"],"URL":"https:\/\/doi.org\/10.1186\/s12887-023-04296-4","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,19]]},"assertion":[{"value":"1 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The sponsor and PIs have obtained approval from the relevant regulatory authorities including SAHPRA (Ref 20221016), University of Cape Town HREC (681\/2022), University of the Witwatersrand HREC (insert) and Stellenbosch University (M23\/02\/004). All major and minor protocol amendments will be submitted to SAHPRA and university ethics committees for approval. Consent to enter the study will be sought from each infant\u2019s mother only after a full explanation has been given, and time allowed for consideration. The PIs will preserve the confidentiality of participants taking part in the study as guided by South Africa\u2019s data protection law, the Protection of Personal Information (POPI) Act 4 of 2013 and will retain all study records and reports for 10\u00a0years following completion of the study. Both the sponsor and the PIs will have access to the final trial anonymised dataset for publication. All authors will meet the ICMJE criteria for authorship and no professional writers will be used. The full protocol will be available online for public access. Any relevant data and results may be published or publicly presented by the investigators.Post-trial access is not applicable for the following reasons:\u2022 Surfactant is only effective in the first few days of life, thus there will be no long-term treatment requirements.\u2022 Aerosolized surfactant is not currently a standard of care anywhere in the world, and should it not be available post-trial, other forms of surfactant delivery (bolus intratracheal surfactant which is the current standard of care) would still be available.\u2022 Should the intervention of aerosolized surfactant prove beneficial in our setting (proof of concept), then this study would be the first step in the development of a cheaper, more accessible drug-device combination for infants in LMICs.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Dr Durand is the chief medical officer at Aerogen Pharma but his contributions to the protocol were of an advisory nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"472"}}